aboutUs_006
聯絡我們English繁體中文簡體中文
logo_isdlogo_isd

Microbio

MENUMENU
MENUMENU
  • ABOUT US
    • ABOUT
    • CORE VALUE
    • COMPANY STRATEGY
    • ESTABLISHMENT HISTORY
    • CORPORATE LOGO
    • Management Team
    • GOVERNANCE STRUCTURE
  • Science And R&D
    • Technology platform
      • SYMBIOTA™
    • Clinical Pipeline
    • Nwe drug
      • MS-20
        • PRODUCT INFORMATION
        • CLINICAL EFFICACY
        • FAQ
        • CONTACT US
      • HERBIRON
    • MEDICAL DEVICES
      • MB-107
      • MB-828
    • Medical nutrition
      • MS-20
      • LT-17
      • MB-901
    • Publication
  • NEWS
  • INVESTORS
    • Corporate Governance
      • GOVERNANCE STRUCTURE
      • CORPORATE GOVERNANCE OFFICER
      • BOARD OF DIRECTORS
      • MAJOR INTERNAL POLICIES
    • Financials
      • MONTHLY REVENUE
      • FINANCIAL REPORTS
    • INVESTOR CONFERENCE
      • INVESTOR CONFERENCE
    • SHAREHOLDERS’ MEETING
      • SHAREHOLDERS’ MEETING
  • ESG
    • SUSTAINABLE MANAGEMENT
      • Message from the Chairman
      • Sustainability Goals and Vision
      • Sustainability Performance
      • Sustainable Management Structure
      • Engagement with Stakeholders and Material Topics Analysis
      • Response to SDGs
    • social inclusion
      • Industry-Academia Collaboration
      • Public Welfare and Donation
      • Actions for Access to Medicines
      • Public participation
      • Supporting Animal Welfare Issues
    • HEALTH CARE
      • Innovative Drugs Research and Development
      • Clinical Trials
      • Drug Safety
      • Supply Chain Management
      • Health Product R&D and Safety
      • Food Quality and Safety
      • Customer Relationship Management
      • Ethical Marketing
    • CORPORATE GOVERNANCE
      • Governance Practices
      • Integrity-Based Operation
      • Internal Audit
      • Risk Management
      • Regulatory Compliance
      • Cyber Security
      • Intellectual Property Rights Protection
    • SAFE WORKPLACE
      • Trustworthy Employer
      • Talent Development and Cultivation
      • Compensation and Benefits
      • Labor Rights
      • Healthy and Safe Working Environment
    • ENVIRONMENTAL PROTECTION
      • Climate Actions
      • Usage of Water Resources
      • Waste Management
      • PackagingMaterialsManagement
      • Environmental Management
      • Carbon Reduction Strategy
    • ESG DATABASE
      • ESG Report
      • Policy Statements and Management System Certificates
    • INTERACTION ZONE
      • STAKEHOLDER QUESTIONNAIRE
  • CAREERS
    • CHOOSE MICROBIO
    • COMPENSATION & BENEFITS
    • JOIN MICROBIO
    • LEARNING DEVELOPMENT
MENUMENU
MENUMENU
  • ABOUT US
    • ABOUT
    • CORE VALUE
    • COMPANY STRATEGY
    • ESTABLISHMENT HISTORY
    • CORPORATE LOGO
    • Management Team
    • GOVERNANCE STRUCTURE
  • Science And R&D
    • Technology platform
      • SYMBIOTA™
    • Clinical Pipeline
    • Nwe drug
      • MS-20
        • PRODUCT INFORMATION
        • CLINICAL EFFICACY
        • FAQ
        • CONTACT US
      • HERBIRON
    • MEDICAL DEVICES
      • MB-107
      • MB-828
    • Medical nutrition
      • MS-20
      • LT-17
      • MB-901
    • Publication
  • NEWS
  • INVESTORS
    • Corporate Governance
      • GOVERNANCE STRUCTURE
      • CORPORATE GOVERNANCE OFFICER
      • BOARD OF DIRECTORS
      • MAJOR INTERNAL POLICIES
    • Financials
      • MONTHLY REVENUE
      • FINANCIAL REPORTS
    • INVESTOR CONFERENCE
      • INVESTOR CONFERENCE
    • SHAREHOLDERS’ MEETING
      • SHAREHOLDERS’ MEETING
  • ESG
    • SUSTAINABLE MANAGEMENT
      • Message from the Chairman
      • Sustainability Goals and Vision
      • Sustainability Performance
      • Sustainable Management Structure
      • Engagement with Stakeholders and Material Topics Analysis
      • Response to SDGs
    • social inclusion
      • Industry-Academia Collaboration
      • Public Welfare and Donation
      • Actions for Access to Medicines
      • Public participation
      • Supporting Animal Welfare Issues
    • HEALTH CARE
      • Innovative Drugs Research and Development
      • Clinical Trials
      • Drug Safety
      • Supply Chain Management
      • Health Product R&D and Safety
      • Food Quality and Safety
      • Customer Relationship Management
      • Ethical Marketing
    • CORPORATE GOVERNANCE
      • Governance Practices
      • Integrity-Based Operation
      • Internal Audit
      • Risk Management
      • Regulatory Compliance
      • Cyber Security
      • Intellectual Property Rights Protection
    • SAFE WORKPLACE
      • Trustworthy Employer
      • Talent Development and Cultivation
      • Compensation and Benefits
      • Labor Rights
      • Healthy and Safe Working Environment
    • ENVIRONMENTAL PROTECTION
      • Climate Actions
      • Usage of Water Resources
      • Waste Management
      • PackagingMaterialsManagement
      • Environmental Management
      • Carbon Reduction Strategy
    • ESG DATABASE
      • ESG Report
      • Policy Statements and Management System Certificates
    • INTERACTION ZONE
      • STAKEHOLDER QUESTIONNAIRE
  • CAREERS
    • CHOOSE MICROBIO
    • COMPENSATION & BENEFITS
    • JOIN MICROBIO
    • LEARNING DEVELOPMENT

ACADEMIC ARTICLE

HomeScience And R&DACADEMIC ARTICLE
Academic Article, EN2025-05-08

MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody_GutMicrobes

Abstract Cancer immunotherapy has been regarded as a promising strategy for cancer therapy by blocking immune checkpoints and evoking immunity to fight cancer, but its efficacy seems to be heterogeneo

108
Read more
Academic Article, EN2025-05-07

Safety Assessment of a Proprietary Fermented Soybean Solution, Symbiota as an Ingredient for Use in Foods and Dietary Supplements_FSN

Abstract A safety evaluation was performed of Symbiota®, which is made by a proprietary anaerobic fermentation process of soybean with multistrains of probiotics and a yeast. The battery of genotoxici

103
Read more
Academic Article, EN2025-05-06

Immune modulation effects of soya bean fermentation food evaluated by an animal model

Abstract A murine model was used to evaluate the role of soya bean fermentation broth (SFB) in immune-modulating a T helper type 1 (Th1)/T helper type 1 (Th2) response. The SFB feeding groups (0.1% an

107
Read more
Academic Article, EN2025-05-05

MS-20, A Chemotherapeutical Adjuvant, Reduces Chemo-Associated Fatigue and Appetite Loss in Cancer Patients

Abstract A small pilot study of the fermented soybean extract MicrSoy-20(MS-20) demonstrated its ability to restore chemotherapy-induced immunosuppression and improve quality of life (QoL). This rando

110
Read more
Academic Article, EN2025-05-04

Bactericidal Activity of Soymilk Fermentation Broth by In Vitro and Animal Models

Abstract Soybean fermentation broth (SFB) exhibits potent antibacterial activity against different species of bacteria in in vitro assays and animal models. Four isoflavone compounds-daidzin, genistin

104
Read more
Academic Article, EN2025-05-03

Chemotherapy-induced immunosuppression is restored by a fermented soybean extract_a proof of concept clinical trial

Abstract Depressed activity of natural killer (NK) cells is often associated with a higher incidence of infection and tumor recurrence. Despite evidence that NK cell activity is depressed after chemot

99
Read more
Academic Article, EN2025-05-02

Antioxidant Activity of Fermented Soybean Extract

Abstract Free radicals are considered to be important causative factors in the development of cancer and cardiovascular diseases. This relationship has led to interest in evaluating the antioxidant ca

91
Read more
Academic Article, EN2025-05-01

Growth Inhibition and Induction of Apoptosis in MCF-7 Breast Cancer Cells by Fermented Soy Milk

Abstract The effect of a fermented soy milk product (FSP) on various human breast carcinoma cell lines was investigated, and it was shown to have a growth-inhibitory effect, especially on MCF-7 cells.

87
Read more
EN, Health Education Area, MS-202024-08-23

Abstract

Abstract A safety evaluation was performed of Symbiota®, which is made by a proprietary anaerobic fermentation process of soybean with multistrains of probiotics and a yeast. The battery of genotoxici

84
Read more
Address:
18 F.-1, No. 3, Yuanqu St., Sanchong Vil., Nangang Dist., Taipei City, Taiwan
TEL: 02-2655-8558
FAX: 02-2655-8559

Longtan Factory Address:
No. 81, Gaoyang N. Road, Longtan District, Taoyuan City , Taiwan
  • Facebook
  • YouTube
版權所有 © 中天生物科技股份有限公司. All Rights Reserved.
Copyright © Microbio Co., Ltd. All Rights Reserved.
隱私權條款 | 使用者條款
privacy policy | Terms of service

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.